Table 1.
Demographic and clinical data of study groups.
| N= | Schizophrenia | Bipolar disorder | Healthy controls | test statistics | p-value |
|---|---|---|---|---|---|
| 20 | 20 | 20 | |||
| Gender distribution (female/male) | 7/13 | 7/13 | 7/13 | χ2 0.000 | 1.000 |
| Age - years (SD) | 31.5 (10.3) | 31.65 (10.0) | 31.5 (10.3) | F 0.001 | .992 |
| Education - years (SD) | 13.6 (3.7) | 13.85 (2.64) | 14.9 (4.52) | F 0.756 | .474 |
| Total intracranial volume - ml (SD) | 1469.31 (27.18) | 1484.58 (37.73) | 1523.80 (33.44) | F 0.710 | .496 |
| Age of disease onset – years (SD) | 25.6 (6.9) | 26.5 (8.8) | n/a | t −0.276 | .784 |
| Duration of disease – years (SD) | 6.0 (7.9) | 5.2 (4.3) | n/a | t 0.297 | .769 |
| Inpatient admissions (min-max) | 1.25 (0–7) | 1.25 (0–4) | n/a | t 0.000 | 1.000 |
| Antipsychotic exposure (CPZE) – mg (SD) | 380.0 (337.3) | 160.8 (272.3) | n/a | t 2.226 | .032 |
| History of psychotic symptoms | 20/20 | 16/20 | n/a | χ2 0.035 | ,106 |
| History of substance abuse | 5/20 | 7/20 | n/a | χ2 0.557 | ,731 |
| History of suicidal behaviors | 4/20 | 4/20 | n/a | χ2 0.000 | 1000 |
| Psychopathology - BPRS (SD) | 35.65 (6.41) | 29.11 (2.61) | n/a | t 3.991 | .000 |
| Functioning – PSP (SD) | 80.22 (12.36) | 92.00 (4.00) | n/a | t −3.845 | .001 |
| Insight – ITAQ (SD) | 17.12 (3.16) | 19.13 (2.22) | n/a | t −2.100 | .044 |
| Schizo-Bipolar Scale (min-max) | 8.00 (7–9) | 0.94 (0–2) | n/a | t 28.356 | .000 |
BPRS = Brief Psychiatric Rating Scale; CPZE = chlorpromazine equivalents; ITAQ = Insight and Treatment Attitudes Questionnaire; PSP = Personal and Social Performance Scale; SD = standard deviation;.